The Hsa_circ_0039857/miR-338-3p/RAB32 Axis Promotes the Malignant Progression of Colorectal Cancer

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2022 Dec 20

PMID 36539702

Authors

Pei Xu

Siying Cheng

Xianwei Wang

Shuming Jiang

Xiaoyan He

Lina Tang

Ning Wu

Zhirong Yang

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC) is a prevalent malignancy of the gastrointestinal. Circular RNAs (circRNAs) act as important roles in CRC malignant progression. However, the role of circ_0039857 in CRC is still unclear. Therefore, this study aimed to explore the function and mechanism of hsa_circ_0039857 in the CRC.

Methods: The mRNA and protein expression were measured via RT-qPCR. RNase R assay and Actinomycin D were employed to evaluate the stability of circ_0039857. Functional experiments, such as proliferation and apoptosis, were applied to study the function of circ_0039857 in CRC cells. The underlying mechanisms of circ_0039857 were then analyzed by bioinformatics, dual-luciferase reporter gene assay, RNA pull-down and rescue experiments.

Results: We revealed that circ_0039857 was significantly enhanced in CRC. Circ_0039857 was stabler than linear RNA in cells and valuable for the disease diagnosis. In addition, circ_0039857 knockdown inhibited proliferation and promoted apoptosis. Mechanistically, circ_0039857 positively regulated the expression of RAB32 via sponging miR-338-3p.

Conclusion: This study demonstrated that circ_0039857 knockdown suppressed CRC malignant progression through miR-338-3p/RAB32 axis. Most importantly, this will help us to better understand the circRNA network in CRC, and may find potential biomarkers and targets for CRC clinical treatment.

Citing Articles

Induction of perineural invasion in salivary adenoid cystic carcinoma by circular RNA RNF111.

Su R, Zhong S, Wang P, Lin Z Clin Transl Oncol. 2023; 25(11):3152-3164.

PMID: 37222950 DOI: 10.1007/s12094-023-03182-w.

References

Shibata D, Mori Y, Cai K, Zhang L, Yin J, Elahi A . RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas. Int J Cancer. 2006; 119(4):801-6. DOI: 10.1002/ijc.21912. View

Tang X, Ren H, Guo M, Qian J, Yang Y, Gu C . Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J. 2021; 19:910-928. PMC: 7851342. DOI: 10.1016/j.csbj.2021.01.018. View

Bao J, Li X, Li Y, Huang C, Meng X, Li J . MicroRNA-141-5p Acts as a Tumor Suppressor Targeting RAB32 in Chronic Myeloid Leukemia. Front Pharmacol. 2020; 10:1545. PMC: 6987442. DOI: 10.3389/fphar.2019.01545. View

Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P . CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017; 16(1):94. PMC: 5440908. DOI: 10.1186/s12943-017-0663-2. View

Yuan H, Liu F, Ma T, Zeng Z, Zhang N . miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2. Open Life Sci. 2021; 16(1):198-209. PMC: 7968531. DOI: 10.1515/biol-2021-0013. View

He J, Wang J, Li S, Li T, Chen K, Zhang S . Hypoxia-inhibited miR-338-3p suppresses breast cancer progression by directly targeting ZEB2. Cancer Sci. 2020; 111(10):3550-3563. PMC: 7540984. DOI: 10.1111/cas.14589. View

Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G . Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2018; 20(5):1836-1852. PMC: 7414524. DOI: 10.1093/bib/bby054. View

Niu Q, Liu Z, Gao J, Wang Q . MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B. Yonsei Med J. 2019; 60(12):1146-1156. PMC: 6881712. DOI: 10.3349/ymj.2019.60.12.1146. View

Zhang M, Wang S . Roles of circular RNAs in colorectal cancer. Oncol Lett. 2021; 22(2):602. PMC: 8227629. DOI: 10.3892/ol.2021.12863. View

10.

Huang J, Yu S, Ding L, Ma L, Chen H, Zhou H . The Dual Role of Circular RNAs as miRNA Sponges in Breast Cancer and Colon Cancer. Biomedicines. 2021; 9(11). PMC: 8615412. DOI: 10.3390/biomedicines9111590. View

11.

Talaat I, Elemam N, Saber-Ayad M . Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol. 2022; 13:810993. PMC: 8841337. DOI: 10.3389/fimmu.2022.810993. View

12.

Wu C, Lui R . Early-onset colorectal cancer: Current insights and future directions. World J Gastrointest Oncol. 2022; 14(1):230-241. PMC: 8790420. DOI: 10.4251/wjgo.v14.i1.230. View

13.

Sun Y, Cao Z, Shan J, Gao Y, Liu X, Ma D . Hsa_circ_0020095 Promotes Oncogenesis and Cisplatin Resistance in Colon Cancer by Sponging miR-487a-3p and Modulating SOX9. Front Cell Dev Biol. 2021; 8:604869. PMC: 7844065. DOI: 10.3389/fcell.2020.604869. View

14.

Li N . CircTBL1XR1/miR-424 axis regulates Smad7 to promote the proliferation and metastasis of colorectal cancer. J Gastrointest Oncol. 2020; 11(5):918-931. PMC: 7657834. DOI: 10.21037/jgo-20-395. View

15.

Piawah S, Venook A . Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019; 125(23):4139-4147. DOI: 10.1002/cncr.32163. View

16.

Lampropoulou D, Pliakou E, Aravantinos G, Filippou D, Gazouli M . The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance. Int J Mol Sci. 2022; 23(3). PMC: 8835818. DOI: 10.3390/ijms23031473. View

17.

Yin Y, Long J, He Q, Li Y, Liao Y, He P . Emerging roles of circRNA in formation and progression of cancer. J Cancer. 2019; 10(21):5015-5021. PMC: 6775606. DOI: 10.7150/jca.30828. View

18.

Simon K . Colorectal cancer development and advances in screening. Clin Interv Aging. 2016; 11:967-76. PMC: 4958365. DOI: 10.2147/CIA.S109285. View

19.

Zhang Y, Zhou M, Li K . MicroRNA-30 inhibits the growth of human ovarian cancer cells by suppressing RAB32 expression. Int J Immunopathol Pharmacol. 2022; 36:20587384211058642. PMC: 8744078. DOI: 10.1177/20587384211058642. View

20.

Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M . Deciphering miRNAs' Action through miRNA Editing. Int J Mol Sci. 2019; 20(24). PMC: 6941098. DOI: 10.3390/ijms20246249. View